Get the Stockscreener App
2.25
44.44%
-1.80
After Hours:
2.32
0.07
+3.11%
Gain Therapeutics Inc stock is traded at $2.25, with a volume of 6.73M.
It is down -44.44% in the last 24 hours and down -21.05% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$4.05
Open:
$3.56
24h Volume:
6.73M
Relative Volume:
5.89
Market Cap:
$86.54M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-2.0455
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-45.26%
1M Performance:
-21.05%
6M Performance:
+25.70%
1Y Performance:
+46.10%
1-Day Range:
$2.14
$3.62
1-Week Range:
$2.14
$4.30
52-Week Range:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.25 | 155.77M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Why Gain Therapeutics Inc. stock could see breakout soon2025 Investor Takeaways & Community Shared Stock Ideas - Улправда
Is Gain Therapeutics Inc. stock a smart buy before Fed meeting2025 Major Catalysts & AI Powered Trade Plan Recommendations - Улправда
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - Yahoo Finance
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data - TipRanks
Gain Therapeutics Announces Phase 1b Study Results for GT-02287 - TradingView — Track All Markets
Gain Therapeutics Reports First-Ever Reduction of Glucosylsphingosine in CSF of Parkinson's Disease Patients in Phase 1b Study of GT-02287 - Quiver Quantitative
Early Parkinson's study links spinal fluid change to brain enzyme shift - Stock Titan
Profit Recap: Can Gain Therapeutics Inc. stock reach $100 price targetDip Buying & Weekly Return Optimization Alerts - Улправда
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
AI and Physics-Based Modeling Identifies a New Parkinson’s Disease Drug - the-scientist.com
Here's why Gain Therapeutics, Inc. (GANX) is a great momentum stock to buy - MSN
Gain Therapeutics At A Crossroads: Will GT-02287 Deliver Disease-Modifying Proof? - RTTNews
How sustainable is Gain Therapeutics Inc stock dividend payoutProfit Target & Consistent Growth Equity Picks - moha.gov.vn
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy - sharewise.com
Gain Therapeutics Inc (GANX) expanding its growth trajectory ahead - setenews.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Winners Losers: Is Gain Therapeutics Inc stock a smart buy before Fed meeting2025 Volume Leaders & Fast Momentum Stock Entry Tips - moha.gov.vn
Gain Therapeutics Announces New Stock Offering Program - MSN
Gain Therapeutics, Inc. (GANX) 5.14% in After-hours: What’s Driving the Move? - Stocks Telegraph
Levels Update: Will Repare Therapeutics Inc. stock gain from lower inflation2025 AllTime Highs & Expert Verified Movement Alerts - moha.gov.vn
FY2025 Earnings Forecast for GANX Issued By HC Wainwright - MarketBeat
HC Wainwright Predicts Higher Earnings for Gain Therapeutics - Defense World
H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data By Investing.com - Investing.com South Africa
Gain Therapeutics (GANX) Stock Analysis Report | Financials & Insights - Benzinga
H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data - Investing.com Canada
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development - MSN
What drives Gain Therapeutics Inc stock priceGrowth vs. Value Investing & Low Cost Market Strategies - earlytimes.in
Gain Therapeutics files prospectus supplement for $35.5 million stock offering By Investing.com - Investing.com Australia
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development - Finviz
Gain Therapeutics files prospectus supplement for $35.5 million stock offering - Investing.com
Gain Therapeutics files prospectus for $35.5 million stock saleSEC filing - marketscreener.com
Gain Therapeutics Files Prospectus Supplement for Stock Offering - TradingView
Can Gain Therapeutics Inc. stock sustain institutional interestTrend Reversal & Smart Allocation Stock Reports - moha.gov.vn
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
Valuation Update: Why Gain Therapeutics Inc. stock could see breakout soonNew Guidance & Daily Technical Stock Forecast Reports - moha.gov.vn
Will Coeptis Therapeutics Holdings Inc. stock gain from government policiesJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
A History of Outperforming Analyst Forecasts and Beating the Odds: Gain Therapeutics Inc (GANX) - setenews.com
Gain Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Rapid Wealth Building Tips - earlytimes.in
How Gain Therapeutics Inc. stock compares to industry benchmarksWeekly Profit Report & Expert Approved Trade Ideas - newser.com
Gain Therapeutics presents data on GT-02287 - TipRanks
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - The Manila Times
Gain Therapeutics (Nasdaq: GANX) Reports GT-02287 Mitochondrial, Neuronal Data - Stock Titan
Will Gain Therapeutics Inc. stock deliver strong dividend growthInsider Buying & Real-Time Volume Analysis Alerts - newser.com
Gain Therapeutics Inc. stock outlook for YEARJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
Is Gain Therapeutics Inc. stock ready for a breakoutWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Can machine learning forecast Gain Therapeutics Inc. recovery2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):